UNIVERSITÀ
DEGLI STUDI
FIRENZE

FLORE

Repository istituzionale dell'Università degli Studi di Firenze

Platelet thromboxane A2 receptors in type I diabetes

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

Original Citation:

Platelet thromboxane A2 receptors in type I diabetes / PA.Modesti; R.Abbate; GF.Gensini; A.Colella; GG.Neri Sernerri. - In: CLINICAL SCIENCE. - ISSN 0143-5221. - STAMPA. - 80:(1991), pp. 101-105.

Availability:

This version is available at: 2158/331744 since:

Terms of use:

Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (<https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf>)

Publisher copyright claim:

(Article begins on next page)

Platelet thromboxane A₂ receptors in type I diabetes

PIETRO AMEDEO MODESTI, ROSANNA ABBATE, GIAN FRANCO GENSINI,
ANDREA COLELLA AND GIAN GASTONE NERI SERNERI

Clinica Medica I, University of Florence, Florence, Italy

(Received 1 February/21 June 1990; accepted 27 July 1990)

SUMMARY

1. Human platelet thromboxane A₂ receptor expression on the membrane surface is possibly dynamically regulated by changes either in the ligand concentration or in membrane fluidity. An increased thromboxane A₂ production and a decreased membrane fluidity has been reported in diabetic patients.

2. In the present study the binding characteristics of platelet thromboxane A₂ receptors have been investigated in nine diabetic patients (type I) and in 15 healthy control subjects by a radioligand-binding method using 9,11-dimethylmethane-11,12-methane-16-[3-¹²⁵I]-4-hydroxyphenyl]-13,14-dihydro-13-aza-15-tetranor-thromboxane A₂ as the radiolabelled ligand.

3. The maximum concentration of binding sites was 163 (sd 35) fmol/10⁸ platelets ($n=15$) with 987 (sd 209) receptors/platelet in controls, whereas in diabetic patients the maximum concentration of binding sites was 74.2 (sd 28) fmol/10⁸ ($n=9$) with 447 (sd 172) receptors/platelet ($P<0.001$). The dissociation constants were 18 (sd 4) nmol/l and 21 (sd 6) nmol/l (not significant) in control subjects and in diabetic patients, respectively. Glycated haemoglobin, which is reported to reduce membrane fluidity, was found to be negatively correlated ($r=0.60$, $P<0.05$) with thromboxane A₂ receptor number in the diabetic patient group. On the contrary, a positive linear correlation between the equilibrium dissociation constant and glycated haemoglobin was found in diabetic patients ($r=0.75$, $P<0.01$).

Key words: diabetes, platelets, receptors, thromboxane A₂.

Abbreviations: $B_{\max}$, maximum concentration of binding sites; HbA_{1c}, glycated haemoglobin; K_d , equilibrium dissociation constant; PTA-OH, 9,11-dimethylmethane-11,12-methane-16-[3-¹²⁵I]-4-hydroxyphenyl]-13,14-dihydro-13-aza-15-tetranor-thromboxane A₂; TxA₂, thromboxane A₂.

Correspondence: Dr P. A. Modesti, Clinica Medica I, University of Florence, Viale Morgagni 85, 50134 Florence, Italy.

INTRODUCTION

An increased thromboxane A₂ (TxA₂) production in response to aggregating stimuli has been reported in platelets from diabetic patients [1–3].

Specific TxA₂-binding sites have been found on the platelet membrane surface [4, 5] and membrane receptors are often dynamically regulated by several factors. Among these a major role is attributed to changes in the ligand concentration [6–9] or to changes in the membrane fluidity [10–12]. An impaired membrane fluidity in blood cells and tissues has been also observed in diabetic patients and related to the increase in protein glycosylation [13, 14]. Therefore the increased TxA₂ synthesis and membrane viscosity could induce changes in platelet TxA₂-binding sites in diabetic patients.

In the present paper the binding characteristics of platelet TxA₂ receptors in patients with type I diabetes mellitus have been investigated by using a ¹²⁵I-labelled derivative (¹²⁵I-PTA-OH) of the 13-azapinane thromboxane antagonist, ONO11120 [5].

METHODS

Materials

ONO11120 (9,11-dimethylmethane-11,12-methane-16-phenyl-13,14-dihydro-13-aza-15-tetranor-TxA₂) [5] was a kind gift of Professor S. Narumiya (Kyoto, Japan). ¹²⁵I-PTA-OH [2000 Ci/mmol; 74 000 GBq/mmol; 9,11-dimethylmethane-11,12-methane-16-[3-¹²⁵I]-4-hydroxyphenyl]-13,14-dihydro-13-aza-15-tetranor-TxA₂], the labelled hydroxylated form of ONO11120, was obtained from Amersham (Amersham, Bucks, U.K.). All the other reagents were obtained from Merck (Darmstadt, F.R.G.) and were of analytical grade.

Subjects

Nine patients with type I diabetes mellitus were investigated. The clinical characteristics of the patients are reported in Table 1. Fluoroangiography was routinely performed and three patients had background retinopathy. All patients were normotensive and no clinical or

Fig. 1. (a) Curves of the displacement of specific ¹²⁵I-PTA-OH binding to human platelets by ONO11120 in control subjects (■) and in diabetic patients (□). (b) Scatchard analysis of ¹²⁵I-PTA-OH binding to platelets from control subjects (■) and diabetic patients (□). The saturation curve is depicted in the inset. B/F, Bound/free.

binding was 0.942 (SD 0.099; $n=7$), suggesting the existence of a homogeneous individual class of binding sites without co-operativity.

Saturation analysis showed saturation of the binding at a ligand concentration about 100 nmol/l (Fig. 1). Scatchard analysis yielded a straight line, indicating a single class of binding sites for ¹²⁵I-PTA-OH (Fig. 1). The equilibrium dissociation constant (K_d) and the maximum concentration of binding sites (B_{max}) had values of 18.1 (SD 3.9) nmol/l ($n=15$) and 163 (SD 35) fmol/10⁸ platelets respectively, with 987 (SD 209) binding sites per platelet ($n=15$).

Scatchard analysis of data obtained in diabetic platelets also yielded a straight line (Fig. 2), with a slightly higher K_d of 21.1 (SD 6) nmol/l ($n=9$). But the intercept with the x-axis (B_{max}) was significantly lower ($B_{max}=74.2$ (SD 28) fmol/10⁸ platelets; $n=9$), with 447 (SD 172) binding sites per platelet ($n=9$) ($P<0.001$) (Table 2). The Hill coefficient for these data was similar to that obtained in control subjects.

Platelet counts and protein concentration in platelet suspensions were comparable in the two groups, as were

Fig. 2. (a) Negative linear correlation between ¹²⁵I-PTA-OH bound and HbA1c in control subjects (■) and diabetic patients (□). $y=341.12-33.52x$; $r=0.66$. (b) Positive linear correlation between K_d and HbA1c in control subjects (■) and diabetic patients (□). $y=-0.69+3.28x$; $r=0.66$.

the percentage of megathrombocytes and mean platelet volume (Table 1). A significant negative linear correlation between platelet receptor number and HbA1c levels was observed both when all subjects were grouped together (Fig. 2) and in the diabetic patient group alone ($r=0.60$, $n=9$, $P<0.05$). On the contrary, a positive linear correlation between K_d and HbA1c was observed both in all subjects (Fig. 2) and in diabetic patients alone ($r=0.75$, $n=9$, $P<0.01$).

DISCUSSION

The present findings indicate that in patients with type I diabetes mellitus, platelet TxA₂ receptors are reduced by about 50%. This result cannot be explained by a reduced volume of platelets in diabetic patients, since the mean platelet volume and the protein concentration in platelet suspension were similar in control subjects and in patients.

In this study diabetic patients were selected on the basis of the absence of cardiovascular complications, so that vascular damage is unlikely to be responsible for the

Table 1. Clinical data for control subjects and diabetic patients

Values are means $\pm$ SD. Abbreviations: FBG, fasting blood glucose concentration; TAG, triacylglycerol concentration; TC, total cholesterol concentration; HDL-C, high-density lipoprotein cholesterol.

	Control subjects (<i>n</i> = 15)	Diabetic patients (<i>n</i> = 9)
Age (years)	55 $\pm$ 10	58 $\pm$ 7.5
Sex (M/F)	13/5	5/4
Weight (kg)	65 $\pm$ 10	60 $\pm$ 12
Duration of diabetes (years)	—	5.5 $\pm$ 5
HbA1c (%)	5.3 $\pm$ 0.6	7.5 $\pm$ 0.66
FBG (mg/dl)	103 $\pm$ 6	138 $\pm$ 31
TAG (mg/ml)	126 $\pm$ 19	141 $\pm$ 33
TC (mg/dl)	186 $\pm$ 32	191 $\pm$ 26
HDL-C (mg/dl)	49 $\pm$ 9	38 $\pm$ 11
Platelet no. (10^6 ml ⁻¹)	242 $\pm$ 22	238 $\pm$ 35
Megathrombocytes (%)	6.8 $\pm$ 1.8	10.1 $\pm$ 2.2
Mean platelet volume (fl)	6.8 $\pm$ 0.2	7.1 $\pm$ 0.3
Protein content (mg/10 ⁹ platelets)	3.5 $\pm$ 0.7	3.6 $\pm$ 0.5

instrumental evidence of peripheral artery disease or ischaemic heart disease was found (Doppler examination, electrocardiogram at rest and on exercise). The control group was composed of 15 clinically healthy subjects of equivalent age. No subject or patient had taken any drug for at least the 15 days preceding the study. All were non-smokers. Informed consent was obtained from each subject investigated.

Blood sampling and platelet isolation

After the subjects had fasted overnight blood was withdrawn by clean venepuncture between 08.00 and 09.00 hours and 15% (v/v) acid-citrate- α -glucose (National Institutes of Health, Formula A) was immediately added. Platelets were washed by centrifugation as described previously [15]. The platelet-rich plasma was adjusted to pH 6.5 with acid-citrate- α -glucose, and centrifuged at 1800 *g* for 30 min at room temperature (20–22°C). Platelets were then resuspended in 10 ml of phosphate buffer (8 mmol/l Na₂HPO₄, 2 mmol/l NaH₂PO₄, 10 mmol/l KCl, 135 mmol/l NaCl, pH 7.2) and again recentrifuged at 1800 *g* for 30 min at room temperature. The supernatant was discarded and the platelets were resuspended in assay buffer containing 138 mmol/l NaCl, 5 mmol/l MgCl₂, 1 mmol/l ethylene glycol bis(aminoethyl ether)tetra-acetate and 25 mmol/l Tris/HCl, pH 7.5. When necessary assay buffer was added to obtain a platelet concentration of 10^9 platelets/ml.

Platelet and megathrombocyte counts were performed by using an electronic counter (Platelet Analyzer 810; Baker Instruments, Allentown, PA, U.S.A.). Megathrombocytes were evaluated as a percentage of platelets counted in the 20–27 μ^3 region. Protein concentration in platelet suspensions was assessed by the method of Lowry *et al.* [16]. Glycated haemoglobin (HbA_{1c}) was evaluated with a column chromatographic method [17].

Binding studies

A portion of the platelet suspension (0.1 ml) was incubated for 10 min at room temperature in a final volume of 0.2 ml with ¹²⁵I-PTA-OH at a final concentration of 0.05 nmol/l (2000 Ci/mmol); plus ONO11120 at increasingly selected concentrations (0–4000 nmol/l). Non-specific binding was considered as the residual radioactivity measured after the addition of ONO11120 at a final concentration of 20000 nmol/l. Non-specific binding of 0.05 nmol/l ¹²⁵I-PTA-OH amounted to 25–35% of total bound radioactivity.

After 10 min incubation, 4 $\times$ 4 ml of ice-cold buffer was added to each tube to stop the reaction, and the content was rapidly filtered under reduced pressure through Whatman GF/C glass microfibre filters. Previous time course experiments showed that under these conditions binding equilibrium was reached [14]. The entire washing procedure was completed within about 15 s. Filters were dried under an air flow and were counted in a Beckman γ -counter with an overall efficiency of 50%. The total binding at each concentration of the displacement curves at equilibrium was determined by dividing the decay per minute (d.p.m.) of each platelet pellet by the calculated specific activity in d.p.m./mol [5, 15]. The analysis of these binding isotherms was performed as described by Scatchard [18].

Statistical analysis

If not otherwise indicated, all data given in the text are means (SD). Each experiment was performed in triplicate and a displacement curve was plotted for each subject. The results were analysed by using Student's *t*-test for unpaired data and by linear regression analysis.

RESULTS

The curve of the displacement of ¹²⁵I-PTA-OH binding by ONO11120 is shown in Fig. 1. The Hill coefficient for the

- deformation induced by chemical agents and/or mechanical forces. *Thromb. Haemostasis* 1989; **62**, 600.
14. Watala, C. *In vitro* glycation of red blood cell proteins: high levels of glucose lower lipid fluidity of erythrocyte membranes. *Exp. Pathol.* 1988; **33**, 233-8.
 15. Modesti, P.A., Colella, A., Abbate, R., Gensini, G.F. & Neri-Serneri, G.G. Competitive inhibition of platelet TxA₂ receptor binding by picotamide. *Eur. J. Pharmacol.* 1989; **169**, 85-93.
 16. Lowry, O.H., Rosebrough, N.J., Farr, A.L. & Randall, R.J. Protein measurement with the Folin-phenol reagent. *J. Biol. Chem.* 1951; **193**, 265-75.
 17. Trivelli, L.A., Ranney, H.M. & Lai, H.T. Haemoglobin components in patients with diabetes mellitus. *N. Engl. J. Med.* 1971; **284**, 353-6.
 18. Scatchard, G. The attraction of protein for small molecules and ions. *Ann. N.Y. Acad. Sci.* 1949; **51**, 660-72.
 19. Jaschonek, K., Faul, C., Schmidt, H. & Renn, W. Desensitization of platelets to iloprost. Loss of specific binding sites and heterologous desensitization of adenylate cyclase. *Eur. J. Pharmacol.* 1988; **147**, 187-96.
 20. Modesti, P.A., Fortini, A., Poggesi, L., Boddi, M., Abbate, R. & Gensini, G.F. Acute reversible reduction of PGI₂ platelet receptors after iloprost infusion in man. *Thromb. Res.* 1987; **48**, 663-9.
 21. Flier, J.S. & Underhill, L.H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. *N. Engl. J. Med.* 1988; **318**, 1315-21.
 22. Rimón, G., Hanski, E., Braun, S. & Levitzki, A. Mode of coupling between hormone receptors and adenylate cyclase elucidated by modulation of membrane fluidity. *Nature (London)* 1978; **276**, 394-6.
 23. Hirata, F. & Axelrod, J. Phospholipid methylation and biological signal transmission. *Science* 1980; **209**, 1082-90.
 24. Muller, C.P. & Krueger, G.R.F. Modulation of membrane proteins by vertical phase separation and membrane lipid fluidity. *Anticancer Res.* 1986; **6**, 1181-94.
 25. Okuma, M., Ushikubi, F., Nakajima, M., Narumiya, S., Fujiwara, M. & Uchino, H. Platelet thromboxane A₂ receptors: purification and properties in normal subjects and altered expression in patients with myeloproliferative disorders. *Thromb. Haemostasis* 1989; **62**, 4.
 26. Abbate, R., Modesti, P.A., Fortini, A. et al. Decreased number of PGD₂ binding sites on platelets from patients with type IIa hyperlipoproteinemia. *Atherosclerosis* 1985; **54**, 167-75.
 27. Schror, K., Lobel, P. & Steinhagen-Thiessen, E. Synvinolin in type IIa hyperlipoproteinemia: normalized platelet hyperreactivity associated with an improved responsiveness against PGI₂ and enhanced PGI₂ receptors. *Thromb. Haemostasis* 1987; **58**, 180-5.